As of November 6, 2026, 2 holders' latest Schedule 13D or 13G filings report owning 5% or more of Voyager Therapeutics, Inc. The largest reported stake is Millennium Management LLC's, at 7.4%. 11 filings are on record since August 14, 2025 (Schedule 13G/A, July 31, 2026).
Sell to companies like Voyager Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Armistice Capital, LLC · Sole voting: 0 · Shared voting: 3,436,000 · Sole dispositive: 0 · Shared dispositive: 3,436,000 · SCHEDULE 13G/A, 2026-08-14
- · Reporting person: Integrated Core Strategies (US) LLC · Sole voting: 0 · Shared voting: 4,437,293 · Sole dispositive: 0 · Shared dispositive: 4,437,293 · SCHEDULE 13G/A, 2026-07-31
- · Reporting person: EcoR1 Capital, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-15
- · Holder: Armistice Capital, LLC · Percent: 5.87% · SCHEDULE 13G/A
- · Holder: The Vanguard Group · Percent: 0% · SCHEDULE 13G/A
Voyager Therapeutics, Inc. has 11 Schedule 13D or 13G filings on record since 2025-08-14. 2 holders' latest filing reports 5% or more of common stock, $0.001 par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Millennium Management LLC | 7.4% | 4,442,951 | SCHEDULE 13G/A, 2026-07-31 | 2026-06-30 |
| Armistice Capital, LLC | 5.58% | 3,436,000 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| EcoR1 Capital, LLC | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
| The Vanguard Group | 0% | 0 | SCHEDULE 13G/A, 2026-03-27 | 2026-03-13 |
Holding shares or following this stake? See who's behind Voyager Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Voyager Therapeutics, Inc. and the records around it.
Voyager Therapeutics, Inc. elsewhere on the record
- Leadership changes Apr 2026
- Who owns it
Companies that share a holder
- EcoR1 Capital, LLC also filed stake reports on 20 other companies: Mereo BioPharma Group plc (Aug 2026), Alto Neuroscience, Inc. (Jul 2026), Fulcrum Therapeutics, Inc. (Jun 2026)
- Integrated Core Strategies (US) LLC also filed stake reports on 63 other companies: SkinHealth Systems Inc. (Nov 2026), Infinite Eagle Acquisition Corp. (Nov 2026), Longeveron Inc. (Nov 2026)
- Armistice Capital, LLC also filed stake reports on 120 other companies: Autolus Therapeutics plc (Aug 2026), Bicycle Therapeutics plc (Aug 2026), BioXcel Therapeutics, Inc. (Aug 2026)
Watch Voyager Therapeutics, Inc.
Get an email when Voyager Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Voyager Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Voyager Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Voyager Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
13 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Integrated Core Strategies (US) LLC | 0 | 4,437,293 | 0 | 4,437,293 | SCHEDULE 13G/A, 2026-07-31 |
| Millennium Management LLC | 0 | 4,442,951 | 0 | 4,442,951 | SCHEDULE 13G/A, 2026-07-31 |
| Millennium Group Management LLC | 0 | 4,442,951 | 0 | 4,442,951 | SCHEDULE 13G/A, 2026-07-31 |
| Israel A. Englander | 0 | 4,442,951 | 0 | 4,442,951 | SCHEDULE 13G/A, 2026-07-31 |
| Armistice Capital, LLC | 0 | 3,436,000 | 0 | 3,436,000 | SCHEDULE 13G/A, 2026-08-14 |
| Steven Boyd | 0 | 3,436,000 | 0 | 3,436,000 | SCHEDULE 13G/A, 2026-08-14 |
| EcoR1 Capital, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| Oleg Nodelman | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| EcoR1 Capital Fund Qualified, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies Voyager Therapeutics, Inc. by CUSIP 92915B106 and gives its principal executive office as 75 Hayden Avenue, Lexington, MA 02421 (SCHEDULE 13G/A, 2026-08-14).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Armistice Capital, LLC | 8.65% | SCHEDULE 13G/A |
| 2025-11-14 | EcoR1 Capital, LLC | 6.8% | SCHEDULE 13G/A |
| 2025-11-14 | Armistice Capital, LLC | 7.57% | SCHEDULE 13G/A |
| 2026-01-26 | Millennium Management LLC | 6.1% | SCHEDULE 13G |
| 2026-02-17 | EcoR1 Capital, LLC | 6.8% | SCHEDULE 13G/A |
| 2026-02-18 | Armistice Capital, LLC | 7.19% | SCHEDULE 13G/A |
| 2026-03-27 | The Vanguard Group | 0% | SCHEDULE 13G/A |
| 2026-05-15 | EcoR1 Capital, LLC | 0% | SCHEDULE 13G/A |
| 2026-05-15 | Armistice Capital, LLC | 5.87% | SCHEDULE 13G/A |
| 2026-07-31 | Millennium Management LLC | 7.4% | SCHEDULE 13G/A |
| 2026-08-14 | Armistice Capital, LLC | 5.58% | SCHEDULE 13G/A |
Questions about who owns Voyager Therapeutics, Inc.
Who owns Voyager Therapeutics, Inc.?
On this page, 2 holders' latest ownership filings report 5% or more of Voyager Therapeutics, Inc.: Millennium Management LLC (7.4%, Schedule 13G/A, filed 2026-07-31) and Armistice Capital, LLC (5.58%, Schedule 13G/A, filed 2026-08-14).
Who are the largest shareholders of Voyager Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Voyager Therapeutics, Inc. on this page are Millennium Management LLC (7.4%) and Armistice Capital, LLC (5.58%).
When did Millennium Management LLC buy into Voyager Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Millennium Management LLC on this page is the Schedule 13G, filed 2026-01-26, reporting 6.1%; its latest, Schedule 13G/A filed 2026-07-31, reports 7.4%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 11 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Voyager Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 21, 2026 | Leadership change: Robin Swartz appointed, President | — | Leadership changes | Source |
| April 21, 2026 | Leadership change: Robin Swartz appointed, Director | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Voyager Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.